Naylor Mark, Elmets Craig, Jaracz Eileen, Rico Joyce M
Oklahoma University Health Science Center, Deerfield, IL 60015, USA.
J Dermatolog Treat. 2005 Aug;16(3):149-53. doi: 10.1080/09546630510041088.
To determine whether atopic dermatitis (AD) patients treated with tacrolimus ointment experienced an increased risk of non-melanoma skin cancer (NMSC).
Data were collected from 9813 adult and paediatric patients with AD who applied 0.03% or 0.1% tacrolimus ointment twice daily and were examined every 3 months during the tacrolimus ointment development programme.
Thirteen adult patients were diagnosed with NMSC during the follow-up period. All patients with NMSC were white adults and 12 were over 40 years of age. Based on 1718 patient-years of tacrolimus ointment exposure in patients 40 years of age, the calculated incidence of NMSC did not suggest an increased risk of first NMSC over that of a similarly aged US cohort.
This study does not indicate an increased risk for the development of NMSC in patients with AD treated with tacrolimus ointment for a mean duration of 208 days with a maximum observation period of 1479 days.
确定接受他克莫司软膏治疗的特应性皮炎（AD）患者发生非黑素瘤皮肤癌（NMSC）的风险是否增加。
收集了9813例成人和儿童AD患者的数据，这些患者每天两次涂抹0.03%或0.1%的他克莫司软膏，在他克莫司软膏研发项目期间每3个月接受一次检查。
在随访期间，13例成年患者被诊断为NMSC。所有NMSC患者均为白人成年人，其中12例年龄超过40岁。基于40岁患者1718人年的他克莫司软膏暴露量，计算出的NMSC发病率并未表明首次发生NMSC的风险高于年龄相仿的美国队列。
本研究未表明接受他克莫司软膏治疗平均208天、最长观察期1479天的AD患者发生NMSC的风险增加。
